PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis
USA - NASDAQ:PTCT - US69366J2006 - Common Stock
63.905 USD
-0.89 (-1.38%)
64.93 USD
+1.03 (+1.6%)
Overall PTCT gets a fundamental rating of 6 out of 10. We evaluated PTCT against 536 industry peers in the Biotechnology industry. PTCT has an average financial health and profitability rating. PTCT is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make PTCT a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
PTCT had positive earnings in the past year.
In the past year PTCT had a positive cash flow from operations.
In the past 5 years PTCT always reported negative net income.
In the past 5 years PTCT always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 23.89%, PTCT belongs to the top of the industry, outperforming 97.39% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 34.54%, PTCT belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.89% | ||
| ROE | N/A | ||
| ROIC | 34.54% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTCT has a Profit Margin of 35.65%. This is amongst the best in the industry. PTCT outperforms 97.01% of its industry peers.
Looking at the Operating Margin, with a value of 49.70%, PTCT belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
With an excellent Gross Margin value of 97.09%, PTCT belongs to the best of the industry, outperforming 96.64% of the companies in the same industry.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 49.7% | ||
| PM (TTM) | 35.65% | ||
| GM | 97.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PTCT is creating value.
PTCT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PTCT has been increased compared to 5 years ago.
Compared to 1 year ago, PTCT has a worse debt to assets ratio.
2.2 Solvency
PTCT has an Altman-Z score of 2.08. This is not the best score and indicates that PTCT is in the grey zone with still only limited risk for bankruptcy at the moment.
PTCT has a better Altman-Z score (2.08) than 65.30% of its industry peers.
The Debt to FCF ratio of PTCT is 3.44, which is a good value as it means it would take PTCT, 3.44 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.44, PTCT belongs to the top of the industry, outperforming 93.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.44 | ||
| Altman-Z | 2.08 |
ROIC/WACC4.31
WACC8.02%
2.3 Liquidity
PTCT has a Current Ratio of 3.62. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT's Current ratio of 3.62 is in line compared to the rest of the industry. PTCT outperforms 42.54% of its industry peers.
PTCT has a Quick Ratio of 3.57. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a Quick ratio of 3.57. This is comparable to the rest of the industry: PTCT outperforms 43.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.57 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 226.85%, which is quite impressive.
PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 96.00%.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
Revenue 1Y (TTM)96%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%
3.2 Future
PTCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.99% yearly.
The Revenue is expected to grow by 16.08% on average over the next years. This is quite good.
EPS Next Y226.6%
EPS Next 2Y18.49%
EPS Next 3Y24.02%
EPS Next 5Y18.99%
Revenue Next Year114.65%
Revenue Next 2Y3.16%
Revenue Next 3Y9.8%
Revenue Next 5Y16.08%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
PTCT is valuated reasonably with a Price/Earnings ratio of 11.27.
97.39% of the companies in the same industry are more expensive than PTCT, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of PTCT to the average of the S&P500 Index (27.76), we can say PTCT is valued rather cheaply.
PTCT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.27 | ||
| Fwd PE | N/A |
4.2 Price Multiples
98.13% of the companies in the same industry are more expensive than PTCT, based on the Enterprise Value to EBITDA ratio.
PTCT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PTCT is cheaper than 98.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.28 | ||
| EV/EBITDA | 4.99 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTCT's earnings are expected to grow with 24.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y18.49%
EPS Next 3Y24.02%
5. Dividend
5.1 Amount
No dividends for PTCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
63.905
-0.89 (-1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.79%
Inst Owner Change0%
Ins Owners0.7%
Ins Owner Change1.33%
Market Cap5.08B
Analysts78.26
Price Target67.93 (6.3%)
Short Float %9.42%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2383.16%
Min EPS beat(2)23.33%
Max EPS beat(2)4742.99%
EPS beat(4)3
Avg EPS beat(4)1137.62%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)4
Avg EPS beat(8)542.76%
EPS beat(12)4
Avg EPS beat(12)346.13%
EPS beat(16)4
Avg EPS beat(16)252.2%
Revenue beat(2)2
Avg Revenue beat(2)293.95%
Min Revenue beat(2)2.58%
Max Revenue beat(2)585.33%
Revenue beat(4)3
Avg Revenue beat(4)147.39%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)4
Avg Revenue beat(8)74.39%
Revenue beat(12)7
Avg Revenue beat(12)50.4%
Revenue beat(16)10
Avg Revenue beat(16)39.02%
PT rev (1m)0%
PT rev (3m)6.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.79%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)27.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.89%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)-0.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.27 | ||
| Fwd PE | N/A | ||
| P/S | 2.88 | ||
| P/FCF | 7.28 | ||
| P/OCF | 7.2 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.99 |
EPS(TTM)5.67
EY8.87%
EPS(NY)-3.58
Fwd EYN/A
FCF(TTM)8.78
FCFY13.74%
OCF(TTM)8.87
OCFY13.88%
SpS22.22
BVpS-2.6
TBVpS-5.45
PEG (NY)0.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.89% | ||
| ROE | N/A | ||
| ROCE | 43.72% | ||
| ROIC | 34.54% | ||
| ROICexc | 4029.4% | ||
| ROICexgc | N/A | ||
| OM | 49.7% | ||
| PM (TTM) | 35.65% | ||
| GM | 97.09% | ||
| FCFM | 39.52% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.44 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 26.13% | ||
| Cap/Sales | 0.42% | ||
| Interest Coverage | 203.36 | ||
| Cash Conversion | 77.86% | ||
| Profit Quality | 110.85% | ||
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.57 | ||
| Altman-Z | 2.08 |
F-Score8
WACC8.02%
ROIC/WACC4.31
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
EPS Next Y226.6%
EPS Next 2Y18.49%
EPS Next 3Y24.02%
EPS Next 5Y18.99%
Revenue 1Y (TTM)96%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%
Revenue Next Year114.65%
Revenue Next 2Y3.16%
Revenue Next 3Y9.8%
Revenue Next 5Y16.08%
EBIT growth 1Y546.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year735.42%
EBIT Next 3Y50.48%
EBIT Next 5YN/A
FCF growth 1Y350.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y384.63%
OCF growth 3YN/A
OCF growth 5YN/A